Overall survival of 30.4 months for bortezomib relapsed patients in Phase 2 of AEZS-108
At the 2011 ASH meeting, Dr. Paul Richardson, MD, Associate Professor in the department of medicine at Harvard Medical School, presented the final data for one of these Phase 1/2 trials which he conducted in 73
Very good results in phase 2 should bring very good results of phase 3 on Monday
patients. Results showed a median overall survival of 25 months for all evaluable patients, including 30.4 months for 20 bortezomib relapsed patients and 22.5 months for 53 bortezomib refractory patients.